Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
CRISPR Therapeutics AG paid$0.00 Mil more to buy back shares than it received from issuing new shares.
It received$0.00 Mil from issuing more debt.
It received$600.00 Mil more from issuing preferred shares than it paid to buy back preferred shares.
It received$0.00 Mil from paying cash dividends to shareholders.
It spent$8.09 Mil on other financial activities.
In all, CRISPR Therapeutics AGearned$591.91 Mil on financial activities for the
three
months ended in Mar. 2026.
CRISPR Therapeutics AG (LTS:0VRQ) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
CRISPR Therapeutics AG's issuance of stock for the
three
months ended in Mar. 2026 was $0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
CRISPR Therapeutics AG's repurchase of stock for the
three
months ended in Mar. 2026 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
CRISPR Therapeutics AG's net issuance of debt for the
three
months ended in Mar. 2026 was $0.00 Mil.
CRISPR Therapeutics AG received$0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
CRISPR Therapeutics AG's net issuance of preferred for the
three
months ended in Mar. 2026 was $600.00 Mil.
CRISPR Therapeutics AG received$600.00 Mil more from issuing preferred shares than it paid to buy back preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
CRISPR Therapeutics AG's cash flow for dividends for the
three
months ended in Mar. 2026 was $0.00 Mil.
CRISPR Therapeutics AG received$0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
CRISPR Therapeutics AG's other financing for the
three
months ended in Mar. 2026 was $-8.09 Mil.
CRISPR Therapeutics AG spent$8.09 Mil on other financial activities.
CRISPR Therapeutics AG Cash Flow from Financing Related Terms
CRISPR Therapeutics AG Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for CRISPR Therapeutics AG's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG Cash Flow from Financing Chart
CRISPR Therapeutics AG Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
CRISPR Therapeutics AG's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,007.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of $1,007.35 Mil mean?
CRISPR Therapeutics AG (LTS:0VRQ) has a Cash Flow from Financing of $1,007.35 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Cash Flow from Financing too high?
CRISPR Therapeutics AG's current Cash Flow from Financing is $1,007.35 Mil. Overall, CRISPR Therapeutics AG has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Cash Flow from Financing compare to MANE and EWTX?
CRISPR Therapeutics AG's Cash Flow from Financing of $1,007.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Cash Flow from Financing is $1,007.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The current Cash Flow from Financing is $1,007.35 Mil. CRISPR Therapeutics AG's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current Cash Flow from Financing is $1,007.35 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
36GF Score
Get the complete analysis for LTS:0VRQ
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0VRQ has been successfully added to your 
